RMgmDB - Rodent Malaria genetically modified Parasites

Back to search results

Summary

RMgm-1366
Malaria parasiteP. berghei
Genotype
MutatedGene model (rodent): PBANKA_1328000; Gene model (P.falciparum): PF3D7_1464600; Gene product: serine/threonine protein phosphatase UIS2, putative (UIS2)
Details mutation: The mutant contains a mutated uis2 gene with two FRT sites
Details conditional mutagenesis: The FRTed sequenmce of uis2 is removed in the sporozoite stage by the Flp/FRT system
Transgene
Transgene not Plasmodium: FlpL recombinase of yeast (FlpL)
Promoter: Gene model: PBANKA_1349800; Gene model (P.falciparum): PF3D7_1335900; Gene product: thrombospondin-related anonymous protein | sporozoite surface protein 2 (TRAP; SSP2; SSP-2)
3'UTR: Gene model: PBANKA_1349800; Gene product: sporozoite surface protein 2 thrombospondin-related anonymous protein (sporozoite surface protein 2; SSP2; SSP-2)
Insertion locus: Gene model: PBANKA_1349800; Gene product: sporozoite surface protein 2 thrombospondin-related anonymous protein (sporozoite surface protein 2; SSP2; SSP-2)
Phenotype Liver stage;
Last modified: 5 April 2016, 10:29
  *RMgm-1366
Successful modificationThe parasite was generated by the genetic modification
The mutant contains the following genetic modification(s) Gene mutation, Introduction of a transgene
Reference (PubMed-PMID number) Reference 1 (PMID number) : 26735921
MR4 number
Parent parasite used to introduce the genetic modification
Rodent Malaria ParasiteP. berghei
Parent strain/lineP. berghei NK65
Name parent line/clone P. berghei NK65 TRAP/FlpL(-)
Other information parent lineTRAP/FlpL(-)(RMgm-268) is a P. berghei NK65 mutant that expresses the yeast Flpl recombinase under the control of the trap promoter. The mutant does not contain a drug-selectable marker (PubMed: PMID: 19380117).
The mutant parasite was generated by
Name PI/ResearcherZhang M; Nussenzweig V
Name Group/DepartmentDepartment of Pathology
Name InstituteNew York University School of Medicine
CityNew York
CountryUSA
Name of the mutant parasite
RMgm numberRMgm-1366
Principal nameuis2 cKO
Alternative name
Standardized name
Is the mutant parasite cloned after genetic modificationYes
Phenotype
Asexual blood stageNot different from wild type
Gametocyte/GameteNot different from wild type
Fertilization and ookineteNot different from wild type
OocystNot different from wild type
SporozoiteNot different from wild type
Liver stageNormal development of sporozoites and invasion of hepatocytes.
No (or strongly reduced) development of liver stages
Additional remarks phenotype

Mutant/mutation
The mutant is a 'Flp/FRT conditional knock-out mutant' of UIS2. The mutant expresses the yeast Flp recombinase under the control of the trap promoter  and contains a mutated uis2 gene that contains two FRT sites. In the mutant the 3’UTR of TRAP together with DHFR flanked by 2 FRT sites were inserted after the stop codon of uis2. This mutant has been generated by replacement of the endogenous uis2 gene by an 'FRTed' uis2 gene in mutant RMgm-268 that expresses Flp.

The uis2 locus locus is disrupted by using the Flp/FRT site-specific recombination (SSR) system (see RMgm-268). Removal of the FRTed uis2 sequence has been achieved by  transmission of the mutant through mosquitoes, thereby activating expression of the Flp recombinase in sporozoites that resulted in the excision of the  uis2 sequence which was flanked by FRT sequences.

Protein (function)
UIS2 is a phosphatase, putative; serine/threonine protein phosphatase, putative.
UIS2 contains a predicted metallo-phosphatase domain enclosed by large N and C-terminal domains.

Plasmodium salivary sporozoites are the infectious form of the malaria parasite and are dormant inside salivary glands of Anopheles mosquitoes. During dormancy, protein translation is inhibited by the kinase UIS1 that phosphorylates serine 59 in the eukaryotic initiation factor 2α (eIF2α). De-phosphorylation of eIF2α-P is required for the transformation of sporozoites into the liver stage. In mammalian cells, the de-phosphorylation of eIF2α-P is mediated by the protein phosphatase 1 (PP1). In this study evidence is presented that in malaria sporozoites, contrary to mammalian cells, the eIF2α-P phosphatase is a member of the PP2C/PPM phosphatase family termed UIS2.

Phenotype
Unsuccessful attempts to disrupt the uis2 gene using standard methods of gene disruption (see RMgm-1364) indicate an essential role of UIS2 during blood stage development.

In the mutant described here the Flp/FRT site-specific recombination (SSR) system of yeast has been used to silence UIS2 expression specifically in sporozoites/liver stages. Removal of the FRTed uis2 sequence has been achieved by  transmission of the mutant through mosquitoes, thereby activating expression of the Flp recombinase in sporozoites that resulted in the excision of the  uis2 sequence which was flanked by FRT sequences.

The uis2 cKO parasite developed normally in the mosquito vector. The number of sporozoites (Ssp) in uis2 cKO and wt parasites was very similar. Next, we compared the phosphorylation levels of eIF2α in Ssp obtained from uis2 cKO and from wt parasites by immunoblot using specific antibodies. We found that phosphorylation of eIF2α was greatly enhanced in the absence of the uis2 phosphatase and the mutant sporozoites invaded HepG2 cells as effectively as wt. Nevertheless, the development of the uis2 cKO Ssp in HepG2 cells was profoundly inhibited two days post-infection: the mutants maintained the sporozoite shape while the wt parasites rounded up and developed into spherical liver stages. In addition, the number of  exo-erythrocytic forms (EEFs) and the P. berghei 18S rRNA of the uis2 cKO parasites were profoundly decreased in the liver stages as compared to the wt parasites When the uis2 cKO sporozoites were injected into mice either by mosquito bite or by intravenous injection, only 4 out of 11 mice were infected as detected by Giemsa staining of blood smears. In addition, the pre-patent day was delayed for 3 days in the 4 mice infected with the uis2 cKO sporozoites as compared to wt. We then examined the genotype of the blood and liver stage parasites originated by uis2 cKO sporozoites. The parasites were uis2 (+) and expressed the UIS2 antigen as the wt, indicating that the uis2 locus had not been completely excised by the recombinase FlpL. The incomplete excision in the FlpL/FRT-mediated conditional mutagenesis system has been previously reported. The overall conclusion of these experiments is that uis2 is essential for liver stage development.

Additional information
Evidence is presented that UIS2 phophatase domain dephosphorylated eIF2α-P and has an activity similar to that of the PP2C/PPM family of phosphatases.

Other mutants
 RMgm-1364: Unsuccessful attempts to disrupt the uis2 gene


  Mutated: Mutant parasite with a mutated gene
Details of the target gene
Gene Model of Rodent Parasite PBANKA_1328000
Gene Model P. falciparum ortholog PF3D7_1464600
Gene productserine/threonine protein phosphatase UIS2, putative
Gene product: Alternative nameUIS2
Details of the genetic modification
Short description of the mutationThe mutant contains a mutated uis2 gene with two FRT sites
Inducable system usedFlp/FRT
Short description of the conditional mutagenesisThe FRTed sequenmce of uis2 is removed in the sporozoite stage by the Flp/FRT system
Additional remarks inducable system
Click to view information
Click to hide information
A recently developed P. berghei conditional mutagenesis approach was utilized that uses stage-specific expression of a temperature-sensitive variant of the yeast recombinase, flippase (FlpL) to catalyze the excision of DNA placed between two Flp Recognition Target sequences (FRT) (see RMgm-268). FlpL catalyzes site-specific DNA recombination at a temperature range of 25°-30°C. The mutant is a 'Flp/FRT conditional knock-out mutant' of UIS2. The mutant expresses the yeast Flp recombinase under the control of the trap promoter and contains a mutated uis2 gene that contains two FRT sites. In the mutant the 3’UTR of TRAP together with DHFR flanked by 2 FRT sites were inserted after the stop codon of uis2. This mutant has been generated by replacement of the endogenous uis2 gene by an 'FRTed' uis2 gene in mutant RMgm-268 that expresses Flp.
Type of plasmid/construct(Linear) plasmid double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid EcoRI
Selectable marker used to select the mutant parasitehdhfr
Promoter of the selectable markerpbdhfr
Selection (positive) procedurepyrimethamine
Selection (negative) procedureNo
Additional remarks genetic modificationThe mutant is a 'Flp/FRT conditional knock-out mutant' of UIS2. The mutant expresses the yeast Flp recombinase under the control of the trap promoter and contains a mutated uis2 gene that contains two FRT sites. In the mutant the 3’UTR of TRAP together with DHFR flanked by 2 FRT sites were inserted after the stop codon of uis2. This mutant has been generated by replacement of the endogenous uis2 gene by an 'FRTed' uis2 gene in mutant RMgm-268 that expresses Flp.
Additional remarks selection procedure
Primer information: Primers used for amplification of the target sequences  Click to view information
Primer information: Primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4
Sequence Primer 5
Additional information primer 5
Sequence Primer 6
Additional information primer 6

  Transgene: Mutant parasite expressing a transgene
Type and details of transgene
Is the transgene Plasmodium derived Transgene: not Plasmodium
Transgene nameFlpL recombinase of yeast (FlpL)
Details of the genetic modification
Inducable system usedFlp/FRT
Additional remarks inducable system The mutant expresses the yeast FlpL recombinase under the control of the promoter of trap. The mutant does not contain a selectable marker. This marker (the hdhfr gene) has been removed from the genome by using the Flp/FRT site-specific recombination (SSR) system. Removal of the hdhfr gene has been achieved by transmission of the mutant through mosquitoes, thereby activating expression of the FlpL recombinase that resulted in the excision of the hdhfr gene that was flanked by FRT sequences.
Type of plasmid/construct(Linear) plasmid double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid
Selectable marker used to select the mutant parasitehdhfr
Promoter of the selectable markereef1a
Selection (positive) procedurepyrimethamine
Selection (negative) procedureNo
Additional remarks genetic modificationThe FlpL coding sequence was flanked by 1.5 kb and 0.6 kb of 5′ and 3′ regulatory sequences of trap, respectively, and associated with a FRTed hdhfr selectable marker containing its own (eef1a) promoter and terminator sequences.
The plasmid was linearized in the 5′ TRAP regulatory sequence to direct gap repair and plasmid integration by single crossover recombination at the homologous chromosomal locus, leaving the endogenous trap gene intact. The plasmid contained the hdhfr selectable marker that is flanked with the 34bp FRT sequences
Additional remarks selection procedure
Other details transgene
Promoter
Gene Model of Parasite PBANKA_1349800
Gene Model P. falciparum ortholog PF3D7_1335900
Gene productthrombospondin-related anonymous protein | sporozoite surface protein 2
Gene product: Alternative nameTRAP; SSP2; SSP-2
Primer information details of the primers used for amplification of the promoter sequence  Click to view information
Primer information details of the primers used for amplification of the promoter sequence  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
3'-UTR
Gene Model of Parasite PBANKA_1349800
Gene productsporozoite surface protein 2 thrombospondin-related anonymous protein
Gene product: Alternative namesporozoite surface protein 2; SSP2; SSP-2
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to view information
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Insertion/Replacement locus
Replacement / InsertionInsertion locus
Gene Model of Parasite PBANKA_1349800
Gene productsporozoite surface protein 2 thrombospondin-related anonymous protein
Gene product: Alternative namesporozoite surface protein 2; SSP2; SSP-2
Primer information details of the primers used for amplification of the target sequences  Click to view information
Primer information details of the primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4